Neos announces U.S. launch of Adzenys XR-ODT for ADHD

 ADHD in the News 2016-05-19

Neos Therapeutics, Inc., a pharmaceutical company with a late-stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in distribution channels and is now available to prescribe for patients with ADHD in the United States.